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SUMMARY Epidermolytic hyperkeratosis (EHK) or bullous 
congenital ichthyosiform erythroderma is a rare autosomal dominant 
disorder characterized by an early onset, with erythroderma and 
bullous lesions, leading to severe generalized hyperkeratosis in 
adulthood. Mutations have been found in keratin 1 and keratin 
10 genes. The clinical manifestations of EHK present striking 
heterogeneity and at least six clinical phenotypes have been 
identified. We report on a case of EHK in a 12-year-old girl with 
erythroderma, erosions and blisters on the entire body surface at 
birth and generalized hyperkeratosis but without severe palm and 
sole involvement in the later stage. On the basis of clinical and 
histopathologic findings, the diagnosis of EHK type NPS-3 was 
made.
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INTRODUCTION
 Epidermolytic hyperkeratosis (EHK, OMIM 113 
800), also termed bullous congenital ichthyosiform 
erythroderma, is a rare genodermatosis with a 
prevalence of approximately 1 in 200,000-300,000 
individuals (1,2). The disorder presents at birth with 
generalized erythroderma and trauma related blis-
tering. With age, these symptoms resolve and are 
replaced by hyperkeratosis, which can be associ-
ated with a diffuse palmoplantar keratoderma. 
 Epidermolytic hyperkeratosis is inherited as an 
autosomal dominant trait, but 50 percent of cases 
may be sporadic due to spontaneous mutations 
(3,4). Genetic analysis of mutations in keratins, re-
sponsible for this disorder, may elucidate the basis 
of significant clinical heterogeneity (5,6). The most 
useful distinguishing feature is the presence or ab-
sence of severe palmoplantar hyperkeratosis (7). 
While there are differences in clinical appearance, 
all variants share a similar histological and ultra-
structural picture (8). 
 We report on a case of EHK characterized by 
an early onset of erythema and blistering of the 
skin following trauma, and widespread hyperker-
atosis but without severe palm and sole involve-
ment in the later stage.
CASE REPORT
 A 12-year-old girl presented with a history of 
generalized erythema and recurrent multiple bul-
lous lesions from birth. The blisters ruptured after 
a minor trauma, leaving areas of denuded skin, 
which healed with hyperpigmentation. No scaring 
was observed. By age 2, she had developed gen-
eralized hyperkeratotic scaling. As hyperkeratosis 
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became more prominent, the skin developed a 
foul smelling odor. There was no family history of 
keratinization disorders. 
 On examination, generalized yellow-brown hy-
perkeratotic plaques were seen, predominantly 
along the joint flexures, scalp, dorsal hands and 
feet. Areas of moderate erythema were seen 
mostly on her trunk (Figs. 1 and 2).
 Palmoplantar surfaces showed minimal hy-
perkeratotic scaling and no digital contractures 
(Fig. 3).
 Routine testing of the blood, urine and stool did 
not reveal any abnormality. Karyotype analysis 
was normal. 
 Skin biopsy revealed marked hyperkeratosis, 
hypergranulosis, acanthosis and vacuolar degen-
eration involving the upper epidermis. The under-
lying dermis showed a scanty perivascular lym-
phoid infiltrate (Fig. 4).
 Oral retinoids could not be used because the 
parents could not afford them.
Figure 1. Generalized hyperkeratotic plaques and 
moderate erythema. 
Figure 2. Hyperkeratotic scaling on the scalp and 
dorsal hands.
DISCUSSION
 The first clinical description of EHK was made 
by Brocq in 1902 (9). He coined the term “bullous 
ichthyosiform erythroderma”, to distinguish the 
entity from nonblistering congenital ichthyosiform 
Figure 3. Minimal hyperkeratotic scale on the 
palms and no digital contractures.
Figure 4. Marked hyperkeratosis, hypergranulosis 
and vacuolar degeneration within the spinous and 
granular layers.
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erythroderma. The term “epidermolytic hyper-
keratosis” refers to the distinctive histopathologic 
feature of vacuolar degeneration and associated 
hyperkeratosis of the epidermis (10).
 EHK is caused by a mutation in the keratin 1 
(K1) and/or keratin 10 (K10) genes linked to chro-
mosomes 12q and 17q (11,12). These mutations 
cause clumped keratin filaments, keratinocyte 
fragility and cytolysis resulting in blister formation 
and hyperkeratosis (13). In addition to scaffold 
abnormalities, the skin of patients with EHK may 
demonstrate a defective permeability barrier func-
tion or altered stratum corneum lipid composition 
(14).
 EHK presents at birth with a varying degree of 
erythroderma, blisters and erosions. Precipitating 
factors for focal blistering include friction, trauma 
and secondary infection. Because of the wide-
spread areas of denuded skin, neonates with EHK 
are at a risk of developing recurrent infection, elec-
trolyte imbalance and sepsis. Gradually, the eryth-
roderma and blisters improve and verrucous hy-
perkeratotic plaques develop, predominantly over 
large flexural joint areas, but can also appear on 
the scalp, neck and infragluteal folds (2,15). The 
scales may become macerated and secondarily 
infected by bacteria leading to a clinically signifi-
cant foul odor. The hair and mucous membranes 
are usually normal, but involvement of the nail ma-
trix may produce abnormal nail plates (16).
 EHK shows phenotypic variability. Involvement 
of the palms and soles occurs in about 60 percent 
of patients with EHK, resulting in soft-tissue con-
tractures of the hands (17).
 DiGiovanna and Bale separated the various 
clinical presentations of EHK into two primary 
types, including NPS (those without severe palm/
sole hyperkeratosis) and PS (those with severe 
palm/sole hyperkeratosis) based on the absence 
or presence of severe palmoplantar hyperkera-
tosis. Furthermore, three distinct subtypes were 
identified into each group, depending on different 
clinical presentation. All of these subtypes present 
with varying degrees of erythroderma, blistering 
and hyperkeratosis (7).
 So far, there was a correlation between the 
presence or absence of severe palm/sole hyper-
keratosis and the specific keratin involved: keratin 
1 mutations were identified in PS types (18) and 
keratin 10 mutations in NPS types (19). 
 Our patient fits the criteria of EHK type NPS-
3, characterized by generalized distribution, no 
severe palm and sole involvement, and no digital 
contractures similar to NPS-1 and NPS-2 type. In 
contrast, in NPS-3 type erythroderma is moderate 
and the palmoplantar surface has minimal scale.
 The diagnosis of EHK can be made clinically 
but laboratory investigation is often required as 
many of the ichthyoses share clinical similarities. 
Skin biopsy specimens from involved areas can 
be submitted to light and electron microscopy as 
well as immunohistochemistry. Electron microsco-
py demonstrates clumping of keratin intermediate 
filaments in the suprabasilar layer. Immunohisto-
chemistry can show a defect in the expression of 
keratin 1 or 10 (20).
 In addition, prenatal diagnosis can be per-
formed by ultrastructural analysis of fetal skin bi-
opsies and amniotic fluid cells, and by direct gene 
sequencing via chronic villus sampling (21). 
 As there is no cure for EHK, the management 
is primarily targeted to symptom reduction. Topical 
emollients including ointments with glycerin, urea, 
lactic acid, and α-hydroxy acid have been shown 
to reduce the symptoms of dryness and improve 
the cosmetic appearance (22). Bogenrieder et al. 
report on safe and successful therapy with topi-
cal calcipotriol (23). For severe cases, systemic 
retinoids may be beneficial in reducing hyperkera-
tosis (24,25), although they may promote desqua-
mation and exacerbate blistering (26).
 EHK is a lifelong condition and the most refrac-
tory form of ichthyosis. Some patients may experi-
ence amelioration of symptoms with age.
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